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Abstract
Diabetes mellitus (DM) is a major public health problem. Cognitive deficits are common with DM which range from subclinical or subtle to 
severe deficits as dementia. Both hypoglycemia and hyperglycemia  are causes of  cognitive impairment with DM. In patients with DM, not 
only severe hypoglycemia but also recurrent mild  or  moderate hypoglycemia have deleterious effect on the brain. Recurrent mild/moderate 
hypoglycemia is associated with intellectual decline, reduced attention, impaired mental abilities and memory deficits. Hypoglycemia may 
result in abnormalities of  neuronal plasticity, synaptic weakening and scattered neuronal death in the cerebral cortex and the hippocampus. 
Chronic hyperglycemia in type 1 and type 2 DM is associated with low IQ (verbal, performance and total) and abnormalities in testing for 
different domains of  cognitive function as verbal relations, comprehension, visual reasoning, pattern analysis, quantitation, memory, learning, 
mental control, psychomotor efficiency, mental and motor processing speed and executive function. The suggested mechanisms incriminated 
in the pathogenesis of  hyperglycemia related cognitive dysfunction include, macro- and micro-vascular disease or vasculopathy, hyperlipi-
demia, hypertension, insulin resistance and hyperinsulinemia, stress response, direct toxic effect of  chronic hyperglycemia on the brain, ad-
vanced glycation end products, inflammatory cytokines and oxidative stress. Hyperglycemia causes oxidative stress, amyloidosis, angiopathy, 
abnormal lipid peroxidation, accumulation of  β-amyloid and tau phosphorylation, neuroinflammation, mitochondrial pathology, apoptosis 
and neuronal degeneration in the cortex and hippocampus. Depression has been identified as a risk for accelerated cognitive decline with 
DM. The knowledge that diagnosis at early age, frequency of  hypoglycemia, poor glycemic control and presence of  risk factors which nega-
tively affect cognitive functions in DM, will have important implications for treatment and for research purposes.
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Introduction 
Diabetes mellitus (DM) is one of  the most common and most 
important metabolic disease worldwide. The incidence and preva-
lence of  DM are increasing rapidly due to industrialization, inap-
propriate diet, sedentary life style and increased obesity [1]. Hy-
poglycemia, hyperlipidemia and vascular diseases (as angiopathy, 
nephropathy and cardiovascular, cerebrovascular and peripheral 
vascular diseases) are common complications of  DM [2]. Cogni-
tive deficits are common with DM which range from subclinical 
or subtle to severe deficits as dementia. Cognition refers to the 
set of  integrated and inter-related mental processes and systems 
involved in acquiring knowledge and comprehending, storing, re-
trieving and using this knowledge to perform day-to-day activities. 
Both hypoglycemia and hyperglycemia  are causes of  cognitive 
impairment with DM [3-39]. Intellectual decline, impaired mental 
abilities and memory deficits are common with recurrent hypo-
glycemic episodes [3-10]. Studies indicate that repetitive mild and 
moderate hypoglycemia cause impairment in synaptic plasticity 
with inability to induce long term potentiation (LTP) which has a 
crucial role in memory and this contributes to cognitive impair-
ments [11,12]. Recurrent moderate hypoglycemia result in scat-
tered neuronal death in the cerebral cortex [13,14] and hippocam-
pus [15]. While severe hypoglycemia result in oxidative stress and 
wide spread neuronal death in the cerebral cortex and hippocam-
pus [16,17]. In hyperglycemia, low IQ and reduced performance 
on various domains of  cognitive function including verbal rela-
tions, comprehension, visual reasoning, pattern analysis, quantita-
tion, digit forward, digit backward, memory, mental control, as-
sociate learning, psychomotor efficiency, problem solving, mental 
and motor processing speed, eye-hand coordination and execu-
tive function, are common [18-26]. The suggested mechanisms 
incriminated in hyperglycemia related cognitive impairment in-
clude: metabolic derangement, macro- and micro-vascular com-
plications [27,28], oxidative stress [29,30] and diabetes-related de-
pression [31-35]. Chronic hyperglycemia causes oxidative stress, 
amyloidosis, angiopathy, abnormal lipid peroxidation, increase the 
formation of  advanced glycation end products, accumulation of  
β-amyloid and tau phosphorylation, neuroinflammation, mito-
chondrial pathology, apoptosis, neurodegeneration in the cortex 
and hippocampus and brain atrophy [36-39].
This review was performed through a comprehensive search in 
the PubMed, ISI web of  science, Science Direct and Scopus data-
bases from 1990 to 2013 using the following search terms: cogni-
tive function in diabetes, hypoglycemia and cognition, type 1 DM 
(T1DM) and cognition and type 2 DM (T2DM) and cognition. 
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Data of  epidemiological, longitudinal, prospective, double-blind-
ed and clinical trial studies and case reports were considered. We 
also checked the reference lists of  the retrieved studies for ad-
ditional reports. In this review, we summarized the experimental 
and clinical evidence of  cognitive dysfunction with DM, the pos-
sible mechanisms underlying cognitive dysfunction in DM, the 
relationship between DM and neurodegeneration and the clinical 
and research approaches with the aim to prevent and treat cogni-
tive dysfunction with DM.
Cognitive Dysfunction With Hypoglycemia
The brain is an energy-intensive organ. Glucose is the primary 
fuel of  brain cells. Approximately 25% of  total body glucose is 
required for proper brain function [40]. The normal range for 
human blood glucose concentration is 3.9 to 7.1 mM (1 mM = ap-
proximately 18 mg/dl). Hypoglycemia is defined as blood glucose 
level below which brain function deteriorates in most patients (i.e. 
less than 3 mmol/l or 54 mg/l00 ml) [41]. In patients with DM, 
not only severe hypoglycemia (blood glucose level below 2 mM) 
but also recurrent mild (blood glucose level is 3.2 to 3.6 mM) or 
moderate (blood glucose level is 2.3 to less than 3.2 mM) hypo-
glycemia have deleterious effect on the brain [3-11,13-17]. Hypo-
glycemia is common with intensive insulin therapy. It has been 
indicated that the oscillations in glycaemia, owing to the nature 
of  subcutaneous insulin administration, are more common and 
result in increase in the frequency of  hypoglycemia in those treat-
ed for DM [42]. Recurrent mild and moderate hypoglycemia are 
more common than severe hypoglycemia [7,10,43]. It has been 
reported that most hypoglycemic events were found to be asymp-
tomatic in 90% of  children treated with insulin, 98% of  those 
occurring at night and the majority of  untreated hypoglycemic 
events were associated with a relapse into hypoglycemia within 
3 hours [44]. Attention, associative learning and mental flexibil-
ity are affected with acute hypoglycemia [5]. Recurrent mild and 
moderate hypoglycemia are associated with intellectual decline 
particularly performance IQ, impaired mental abilities and mem-
ory deficits [3,45]. It was reported that recurrent mild and moder-
ate hypoglycemia in children younger than 5 years old with T1DM 
may develop reduced attention, spatial memory and intelligence in 
adolescence [6,8,46].
Experimental and clinical studies indicate that severe hypogly-
cemia for a least 10 minutes result in microglial activation and 
oxidative stress with the release of  several neurotoxic substanc-
es, including superoxide, nitric oxide, and metalloproteinase and 
wide spread neuronal death in the cerebral cortex and hippocam-
pus. While recurrent moderate hypoglycemia result in scattered 
neuronal death in the second and third cerebral cortex layers and 
hippocampal CA1 dendritic region and hippocampal thinning 
[14-16,47,48]. It has been suggested that cognitive impairment in 
children and adults with repetitive mild and moderate hypoglyce-
mia is due to deterioration in synaptic injury with an inability to 
induce or persistent inhibition of  long term potentiation (LTP) 
and facilitation of  long term depression (LTD) at hippocampal 
CA1 (which plays a crucial role in memory) in the absence of  
apparent neuronal somatic injuries. This in turn results in activity-
dependent synapse weakening and contributes to cognitive im-
pairments [11,12].
Cognitive Dysfunction With Hyperglycemia
DM is defined by the presence of  symptoms of  hyperglycemia 
and presence of  fasting plasma glucose (FBG) level ≥ 7.0 mmol/l 
or126 mg/dl or post-prandial blood glucose (PBG) ≥ 11.1 mmol/l 
or 200 mg/dl or a random plasma glucose ≥ 11.1 mmol/l or 200 
mg/dl or glycated hemoglobin (HbA1C) ≥ 6.5% [49].
At the experimental level, detrimental effects on learning and 
memory were observed in streptozotocin (STZ) (rodent model 
of  T1DM) and GK rat [50], db/db mouse and Zucker rat [51] 
(genetic models of  T2DM) as observed with impaired perfor-
mance in Morris water maze spatial test [51,52] and inhibitory 
[53] or active avoidance tasks [54] and an object-discrimination 
task tests [22], all are indicative of  impairment in hippocampus 
and its related structures. At the clinical level, children and adults 
with DM demonstrate low IQ and reduced performance on 
various domains of  cognitive function including verbal relations, 
comprehension, visual reasoning, pattern analysis, quantitation, 
digit forward, digit backward, short-term memory, memory for 
sentences, verbal memory, logical memory, mental control, asso-
ciate learning, psychomotor efficiency, problem solving, mental 
and motor processing speed, eye-hand coordination and execu-
tive function [18-26,55-57]. Many authors reported that cognitive 
deficits were correlated with the degree of  chronic hyperglycemia 
and improvement in performance of  cognitive testing with im-
provement in glucose tolerance [58,59]. Wu et al. [23] observed 
that compared to treated patients, the untreated patients with DM 
had 2 points decline over 2 years on Mini Mental State Examina-
tion test (MMSE) with duration of  illness <5 years and 6 points 
decline on MMSE with duration of  illness ≥5 years. Cox et al. [24] 
observed that the increase of  blood glucose >15mmol/l was as-
sociated with marked decline in cognition and poor performance 
in arithmetic tasks. The research showed that those with DM have 
a 1.2 to 1.5-fold greater rate of  decline in cognitive function com-
pared to those without diabetes [60]. At the neurophysiological 
level, studies also reported abnormalities in P300 component of  
event related potentials (ERPs), a physiological analogue of  cogni-
tive testing [25,61,62] and prolongation of  I-III and I-V interpeak 
latencies of  the auditory brainstem response (ABR), an indicative 
of  central auditory pathway function [63], in patients with T1DM 
and T2DM and regardless of  the recent metabolic derangement 
and disease duration.  At the neuroimaging level, structural brain 
atrophy particularly in the limbic structures such the hippocam-
pus and amygdala, smaller total brain volume, smaller gray matter 
volume, larger ventricular volume, larger white matter lesion vol-
ume and accelerated increase in ventricular volume over time and 
increased risk for incident brain infarcts, were seen in magnetic 
resonance imaging (MRI) of  the brain of  patients with T2DM 
and also in patients with early manifestation of  impaired glucose 
tolerance (i.e. PBG ≥140 mg/dl or 7.8 mmol/L but not over 200 
mg/dl or 11.1 mmol/L) [28,38,39,64-66]. Studies also reported 
that well-controlled middle-aged individuals with T2DM [20], 
non-diabetic individuals with insulin resistance (IR) (a pre-dia-
betic state) [67] had declarative memory deficits and specific hip-
pocampal volume reduction and deficits in hippocampal synaptic 
plasticity [52] which were correlated with the present deficits in 
declarative memory. 
The etiology of  cognitive impairment in people with hypergly-
cemia is multifactorial. Vascular [27,28] as well as neurodegena-
tion [65,66] contribute to cognitive dysfunction with chronic hy-
perglycemia.  The followings have been suggested as causes of  
hyperglycemia-induced cognitive impairment: chronic complica-
tion as macro- and micro-vascular complications (diabetic vascu-
lopathy) [20,27,28], hyperlipidemia [68,69], hypertension [70,71], 
insulin resistance (IR) and hyperinsulinemia [67], dysregulation of  
limbic-hypothalamic-adrenal pituitary axis (LHPA) with chronic 
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hypercortisolemia and impairments in hippocampal neurogen-
esis, synaptic plasticity and learning [72-74], direct toxic effect of  
chronic hyperglycemia on the brain [25,55], advanced glycation 
end products, inflammatory cytokines, oxidative stress [29,30] and 
diabetes-related depression [32-35].
DM is a risk for arterial stiffness and atherosclerotic and cerebro-
vascular diseases [27,28]. Experimental and human studies also 
indicate that chronic hyperglycemia result in brain injury with spe-
cific vulnerability to memory and learning processing, regardless 
of  vascular pathology. In experimental models, it was observed 
that chronic hyperglycemia and spontaneous onset of  T2DM 
cause blood brain barrier (BBB) disruption, alteration of  insulin 
transporter and decrease in insulin receptors which are expressed 
in discrete neuronal populations in the CNS, including the hip-
pocampus. Impairment of  insulin function result in reduction in 
the uptake of  glucose into the neurons, impairment of  energy me-
tabolism and impairment of  brain’s capacity to generate the con-
nections vital to memory and learning. Reduction of  insulin like 
growth factor 1 (ILGF-1) [75,76] and brain derived neurotrophic 
factor (BDNF) were observed in rat models of  T2DM [77]. IGFs 
regulate adult brain mass by maintaining brain protein content 
and supports synapses and is required for learning and memory. It 
was observed that replacement doses of  insulin and IGFs in dia-
betic rats can cross the blood-brain barrier, improve brain atrophy 
and prevent hippocampus-dependent memory impairment [75-
77]. Researchers found that insulin and IGF-I were significantly 
reduced in the frontal cortex, hippocampus and hypothalamus 
but not the cerebellum in postmortem brain tissue from people 
with DM [45].  It has been indicated that hyperglycemia causes 
oxidative stress, amyloidosis, angiopathy, abnormal lipid peroxida-
tion, increase the formation of  advanced glycation end products, 
accumulation of  β-amyloid and tau phosphorylation, neuroin-
flammation, mitochondrial pathology, increase in Bax expression 
(proapoptotic protein) and caspase-3 (apoptotic element) levels, 
reduction in Bcl-2 protein levels (antiapoptotic protein), increase 
in the ratio of  Bax to Bcl-2, DNA fragmentation in the cortex and 
hippocampus, neuronal degeneration and brain atrophy [36,37]. 
Recently, it was reported that adults and middle aged patients with 
T2DM had higher concentrations of  serum neuron specific eno-
lase (NSE) (which is a marker of  neuronal cell damage which 
was significantly correlated with cognitive deficits’ regardless the 
level of  glycemic control and after adjustment of  confounders 
[25]), indicating direct brain injury due to chronic hyperglycemia. 
Several studies have shown higher serum and cerebrospinal fluid 
(CSF) levels of  NSE and also their over-expression increases the 
vulnerability to neurodegeneration, cerebral hypoxic-ischemic in-
jury and traumatic brain injury [78,79]. 
Cognitive Dysfunction With Hyperinslinemia
Insulin is a key protein in the control of  intermediary metabolism. 
It organizes the use of  fuels for either storage or oxidation. It  in-
fluences carbohydrate, lipid, protein and mineral metabolism [40]. 
Binding of  insulin to its receptors phosphorylates many intra-
cellular protein and generating a biological response. Insulin acts 
on cells thoughout the body to stimulate uptake, utilization and 
storage of  glucose. In the brain, as with peripheral insulin, insulin 
is in part responsible for the uptake of  glucose into the neurons 
which is important for energy metabolism. Most of  brain insulin 
originates from systemic blood circulation but to less extent, it is 
produced in the brain [80]. Insulin crosses the blood-brain barrier 
(BBB) using a saturable transporter [81]. Insulin-sensitive glucose 
transporters, insulin receptors and insulin downstream signaling 
molecules, are distributed throughout the human brain on both 
neurons and astrocytes [82]. Insulin receptors are densely ex-
pressed in the medial temporal lobe, hippocampus and prefrontal 
cortex, which mediate long-term memory and working memory 
[83]. Insulin affect a wide range of  normal brain functions, such as 
reward, motivation, cognition, attention and memory formation. 
Insulin’s anabolic effect in the brain includes stimulation of  the 
growth, neuronal differentiation, survival (neurotropism) and re-
modeling (neuromodulation) [82]. The synapses (which transmit 
information between neurons) contain insulin receptors. Insulin 
serves as a vital element for normal synaptic structure and func-
tion and subsequently for the strength of  connections between 
neurons.  Insulin binds to receptors at the synapse and together 
with proper inulin signaling, both contribute to brain plasticity 
and formation of  new brain circuitries essential for learning and 
memory [84]. Insulin in the brain is degraded by insulin degrad-
ing enzyme (IDE). IDE regulates the generation and clearance of  
amyloid β (Aβ) from the brain[85,86]. 
Hyperinsulinemia is a most common consequence of  IR which is 
the main defect in T2DM. It has been indicated that prolonged 
exposure of  the brain to higher than physiological levels of  insu-
lin may alter signaling and metabolic pathways in a manner that is 
deleterious to cognitive circuitry which mainly depends on proper 
metabolic processes [84]. Chronic elevation of  insulin concentra-
tions in the periphery may paradoxically causes a relative hypo-
insulinized state in the brain and thus resultant hyperinsulinemia 
could actually impair cognition by disturbing insulin-mediated 
utilization of  glucose by cells in the brain particularly the hip-
pocampus, which is enriched with insulin receptors. Central hy-
poinsulinemia may promote central inflammation, β-amyloid 
generation and reduced neuroplasticity [85]. Decrease in levels of  
insulin degrading enzyme (IDE) was observed in rat models of  
T2DM. IDE, an enzyme responsible for insulin degradation in 
the brain, also degrades amyloid plaque. As insulin has a very sim-
ilar molecular structure to amyloid plaque, thus the latter might 
compete for the benefits of  IDE in presence of  hyperinsulinemia 
[86]. Elevated insulin levels are implicated in the brain cells’ failure 
to clear β-amyloid, formation of  senile plaques and tau protein 
phosphorylation[87-89].
Depression Accelerates Cognitive Decline With 
Dm
Epidemiological studies suggested that diabetic patients are 2-3 
fold more likely to develop depressive illness when compared 
to non-diabetic individuals. On the other hand, individuals with 
depression have an approximately 60 percent higher risk of  de-
veloping T2DM [32-34] In general, the prevalence of  depression 
with DM was estimated to be 31.1% [90]. Comorbid depression 
has been identified as a risk factor for accelerated cognitive de-
cline among patients T2DM. Depression has been identified as 
a risk factor for dementia among patients with T2DM in all do-
mains [35].
Clinical and Research Perspectives
The knowledge that diagnosis at early age, frequency of  hypogly-
cemia, poor glycemic control and presence of  risk factors which 
negatively affect cognitive functions in DM, will have important 
implications for treatment of  DM and for research purposes. 
Preventive strategies include modification of  lifestyle, patient 
education, diet orientations (i.e. eliminating high-glycemic foods, 
including processed carbohydrates and sweets, would sensitize 
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insulin receptors and correct hyperinsulinemia [91-94]), stopping 
smoking, maintaining a healthy body weight, mental and physical 
exercise [95], control of  hypertension and dyslipidemia and treat-
ment of  brain infarcts, cardiovascular diseases and depression 
[70,96,97]. In hyperglycemia, it is important to regularly monitor 
the blood glucose level and to keep glycemic control with the aim 
is an HbA1C level of  6.5%, but should not be lower than that, 
and may be set higher [98]. Hypoglycemia should be treated with a 
defined dose of  carbohydrates rather than a mixed meal. Insulin-
sensitizing drug are able to slow down, prevent, or perhaps even 
improve DM-related cognitive decline. Neuroprotective strate-
gies have to be included aside to the treatment of  DM from the 
beginning to prevent the long-term diabetic complications, those 
include: free radical scavengers/antioxidants (as alpha lipoic acid 
(ALPA), evening primrose oil (EPO), vitamin C, vitamin E and 
vitamin B complex) [99], modifiers of  mitochondrial dysfunction, 
anti-apoptotics, and neurotrophic factors [76]. Future studies has 
to be directed for better understanding of  the pathophysiologi-
cal mechanisms underlying the cognitive dysfunction in diabetes. 
There is also a need for construction of  longitudinal studies that 
prospectively assess the relation of  the disease process to cogni-
tion over time and randomized clinical trials that compare cogni-
tive function in DM patients receiving memory enhancers, antide-
pressants, versus a control group of  DM patients. 
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